Dated: November 21, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–30539 Filed 11–29–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, DHH.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7057; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Image Registration Using Voxel Gradients With an Iterative Registration Process

J Ostuni (LDRR)

Serial No. 60/016,429 filed 29 Apr 96

Licensing Contact: John Fahner-Vihtelic, 301/496–7735 ext. 285

To date, it has been difficult to combine or compare images which represent a similar scene using different and unrelated intensities, for example, two magnetic resonance volumes taken with different sequences. The current invention represents a means by which this difficulty may be overcome, and embodies an algorithm which allows for the registration or the ''matching up'' of multiple three-dimensional images. Specifically, the algorithm is based upon finding the correspondence of closest gradient voxels, where a gradient voxel is any voxel containing a high 3D intensity gradient. Typically, gradient voxels represent areas of change within the image. This algorithm can successfully perform registrations under conditions of unrelated voxel intensity, significant object motion and/or significant amounts of missing data. The invention, therefore, represents a powerful new tool for users of a variety of three-dimensional systems. (portfolio: Devices/Instrumentation—Other)

Compositions for the Prevention or Retardation of Cataracts

JS Zigler Jr., P Russell, S Tumminia, C Qin, CM Krishna (NEI)

Serial No. 60/010,637 filed 26 Jan 96

Licensing Contract: J. Peter Kim, 301/496–7056, ext. 264

Oxidative stress is becoming recognized a major problem, and free radicals and activated oxygen species are recognized as agents of tissue damage associated with a number of conditions. Aging-related cataract is a disease of multifactorial origin involving many of the same processes which characterize the process of aging in other tissues. It appears that once cataractogenesis has begun, the process of cataract development may proceed via one or more common pathways or processes. The subject invention focuses on intervening at the level of these common pathways in hopes of stopping or slowing the progression of the disease process. The present invention provides methods and compositions for the prevention and treatment of cataract formation which comprise a nitroxide free radical compound or its hydroxylamine and a thiol reducing agent. (portfolio: Ophthalmology—Therapeutics, chemical)

Molecular Cloning and Characterization of a Differentiation Antigen, CAK1, Present on Mesothelium, Mesotheliomas and Ovarian Cancers

I Pastan, K Chang (NCI)

Serial No. 60/010,166 filed 05 Jan 96

Licensing Contact: Larry Tiffany, 301/496–7056 ext 206

CAK1, or ''mesothelin'', is an antigen present on the cell surface in mesothelium and on many mesotheliomas and ovarian cancers. While the role of this differentiation antigens has not yet been determined, it is postulated that it may be implicated in adhesion and in the dissemination of mesotheliomas and of ovarian cancers. CAK1, therefore, is a potential target for monoclonal antibodies to be used in the diagnosis and treatment of these cancers. The gene for CAK1 has been cloned and sequenced, as embodied in the current invention. The invention, therefore, should provide a valuable research tool for use in the development of diagnostics and/or therapeutic agents toward mesotheliomas and ovarian cancers. (portfolio: Cancer—Research Materials, DNA based)

Method of Mobilizing Pluripotential Hematopoietic Stem Cells With IL–7

RH Wiltrout, F Ruscetti, K Grzegorzewski, J Keller, KL Komschlies-McConville (NCI)

Serial No. 08/341,399 filed 16 Nov 94

Licensing Contact: Jaconda Wagner, 301/496–7735 ext 284

This invention provides a method of increasing numbers of hematopoietic stem cells in a subject by administering interleukin–7 to the subject. Hematopoietic stem cells are distinguishable from hematopoietic progenitor cells in that the stem cells are pluripotent and not yet committed to myeloid or lymphoid lineages. After treatment, a population of leukocytes enriched for hematopoietic stem cells may be isolated from the subject's peripheral blood. Such a population of leukocytes enriched from hematopoietic stem cells may be transferred into a recipient in order to enhance the repopulation of the recipient's hematopoietic and immune cells. In addition, the method provides for improved engraftment of a bone marrow transplant in a recipient following transplantation or irradiation. A Notice of Allowance has recently been issued for this patent application. (portfolio: Internal Medicine—Therapeutics; Cancer—Therapeutics; biological response modifiers, growth factors)

Dated: November 20, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–30538 Filed 11–29–96; 8:45 am]

BILLING CODE 4140–01–M

Office of the Secretary

Notice of Meeting of the Human Genetics Subcommittee of the National Bioethics Advisory Commission (NBAC)

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), this notice is hereby given to announce an open meeting of The Human Genetics Subcommittee of the National Bioethics Advisory Commission (NBAC). The purpose is to discuss issues regarding the use of genetic information and technologies.

DATES: Friday December 13, 1996, 7:30 a.m. to 3:30 p.m.

PLACE: National Institutes of Health, Building 31 C wing, 6th Floor, Conference Room 9, Bethesda, Maryland 20892.

SUPPLEMENTARY INFORMATION: The President established the National